Skip to main content
Eli LillyIn development

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one...

Source: Autobound Signal API · 114 signals tracked for Eli Lilly · updated

Get Eli Lilly's live signals in Claude or ChatGPT, or by API

AskWhat changed at Eli Lilly this week? Use Autobound signals for lilly.com.

What happened

Eli Lilly announced detailed 52-week results from its Phase 3b TOGETHER-PsA clinical trial evaluating the concomitant use of Taltz and Zepbound.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Nearly three times as many patients taking Taltz and Zepbound achieved ≥ 50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA study Improvements in disease activity at one year follow statistically superior outcomes observed with Taltz and Zepbound vs. Taltz alone at Week 36 primary endpoint Detailed data were featured as an oral presentation at ACR Convergence 2026 and simultaneously published in Arthritis & Rheumatology INDIANAPOLIS, Nov. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced detailed 52-week results showing improved and durable efficacy from the TOGETHER-PsA Phase 3b open-label clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one additional weight-related comorbid condition. New detailed exploratory analyses showed treatment with Taltz and Zepbound used together maintained or further improved outcomes across disease activity, patient-reported and metabolic measures through Week 52. As previously reported, treatment with Taltz and Zepbound met the primary and all key secondary endpoints for statistically significant superiority to Taltz alone at 36 Weeks. The 52-week findings were presented at the...

Keep reading with a free account

The rest of this article, and every signal for Eli Lilly, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
Taltz and Zepbound
Takes effect
Nov 11, 2026
Location
Indianapolis, Indiana, United States

The full record

From the Signal API record

Details

Ticker
NYSE:LLY

Topics and mentions

Product tags

  • medical
  • general technology

Extraction

Confidence
95%
Detected
Nov 11, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Eli Lilly and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Eli Lilly this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/762e9020-d8bd-aa82-a0eb-cad43f80d9de returns this record as JSON. POST /v1/companies/enrich returns every signal for lilly.com.

{
  "signal_id": "762e9020-d8bd-aa82-a0eb-cad43f80d9de",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-11T14:45:00+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/new-phase-3b-data-on-lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-showed-improved-and-durable-efficacy-patient-reported-and-metabolic-outcomes-at-one-year-in-adults-with-psoriatic-arthritis-and-obesity-302935708.html",
    "title": "New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity",
    "ticker": "NYSE:LLY",
    "excerpt": "Nearly three times as many patients taking Taltz and Zepbound achieved ≥ 50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA study Improvements in disease activity at one year follow statistically superior outcomes observed with Taltz and Zepbound vs. Taltz alone at Week 36 primary endpoint Detailed data were featured as an oral presentation at ACR Convergence 2026 and simultaneously published in Arthritis & Rheumatology INDIANAPOLIS , Nov. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced detailed 52-week results showing improved and durable efficacy from the TOGETHER-PsA Phase 3b open-label clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one additional weight-related comorbid condition. New detailed exploratory analyses showed treatment with Taltz and Zepbound used together maintained or further improved outcomes across disease activity, patient-reported and metabolic measures through Week 52. As previously reported, treatment with Taltz and Zepbound met the primary and all key secondary endpoints for statistically significant superiority to Taltz alone at 36 Weeks. The 52-week findings were presented at the...",
    "product": "Taltz and Zepbound",
    "summary": "Eli Lilly announced detailed 52-week results from its Phase 3b TOGETHER-PsA clinical trial evaluating the concomitant use of Taltz and Zepbound.",
    "location": "Indianapolis, Indiana, United States",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS270365/ELI-LILLY-AND-COMPANY-LOGO.jpg?id=OA3070331&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "Taltz and Zepbound",
      "full_text": "concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-11-11T14:45:00Z",
    "location_data": [
      {
        "city": "Indianapolis",
        "state": "Indiana",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-11",
    "article_sentence": "Eli Lilly and Company (NYSE: LLY ) today announced detailed 52-week results showing improved and durable efficacy from the TOGETHER-PsA Phase 3b open-label clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one additional weight-related comorbid condition."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.